Valuation: China Biotech Services Holdings Limited

Market Cap 585M 74.63M 64.64M 61.13M 55.34M 104M 7.16B 105M 729M 281M 3.63B 280M 274M 11.58B P/E 2024
-2.49x
P/E 2025 -11.2x
Enterprise Value 968M 123M 107M 101M 91.53M 172M 11.84B 173M 1.21B 464M 6B 464M 453M 19.15B EV / Sales 2024
9.45x
EV / Sales 2025 15.7x
Free-Float
35.46%
Yield 2024 *
-
Yield 2025 -
Aug. 28 China Biotech Services Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2026 CI
Aug. 12 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026 CI
Aug. 11 China Biotech Services Holdings Limited and Stella Pharma Corporation Enter Master Collaboration Agreement for Commercialisation of BNCT Drug CI
Aug. 03 China Biotech Services Holdings Limited's Japan, Pengbo Medical Technology Co., Ltd. Present of Initial Follow-Up Findings of Boron Neutron Capture Therapy At the 22Nd Congress on Neutron Capture Therapy CI
May. 18 China Biotech Services' unit disposes entire stake in PHC Medical Diagnostic Centre, others RE
Apr. 30 China Biotech Services says He Xun resigns as executive director RE
Apr. 30 China Biotech Services Holdings Limited Announces Resignation He Xun as Executive Director, Effective May 1, 2026 CI
Apr. 28 China Biotech Services Holdings Limited Auditor Raises 'Going Concern' Doubt CI
Mar. 27 China Biotech Services Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
Mar. 06 China Biotech Services expects FY net loss of not more than HK$100 million RE
Mar. 06 China Biotech Services Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2025 CI
Feb. 19 China Biotech Services Holdings Limited announced that it has received HKD 272.3 million in funding from Wealth Strategy Holding Ltd CI
Dec. 29 China Biotech Services to issue convertible bonds RE
1 week-1.64%
Current month+5.26%
1 month-4.00%
3 months+17.65%
6 months-14.29%
Current year-24.05%
1 week 0.58
Extreme 0.585
0.64
1 month 0.5
Extreme 0.5
0.67
Current year 0.3
Extreme 0.3
0.92
1 year 0.3
Extreme 0.3
1.14
3 years 0.25
Extreme 0.25
1.33
5 years 0.25
Extreme 0.25
2.64
10 years 0.16
Extreme 0.159
2.64
Manager TitleAgeSince
Director of Finance/CFO - -
Compliance Officer 55 2022-05-25
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 60 2017-08-06
Director/Board Member 44 2017-09-14
Chairman 55 2017-08-27
Date Insider Type Main position Quantity % Market Cap. Importance
3/30/26 Other

Chairman

3,600,000 0.3690%
9/2/24 Other

Director

3,220,000 0.3300%
6/13/24 Other

Director

5,000,000 0.5191%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.64%-44.95%0.00% 74.63M
-1.11%-1.64%+28.63%+33.33% 121B
-0.39%+5.42%+5.12%+65.37% 91.76B
-0.69%+1.58%-3.14%+52.16% 29.51B
+3.86%+4.92%+36.80%+95.75% 27.27B
-0.43%-0.78%-4.24%-2.58% 21.46B
-1.38%+0.69%+39.68%+273.82% 21B
-0.30%-1.39%-7.00%+28.35% 15.65B
+0.56%+2.55%-5.42%-5.26% 12.17B
+0.83%+6.02%+45.78%+94.14% 12.17B
Average +0.10%+1.69%+9.13%+63.51% 35.19B
Weighted average by Cap. -0.32%+1.65%+16.94%+60.80%

Financials

2024 2025
Net sales 70.51M 8.99M 7.79M 7.36M 6.67M 12.51M 862M 12.6M 87.86M 33.8M 437M 33.76M 33.01M 1.39B 73.5M 9.37M 8.12M 7.67M 6.95M 13.04M 899M 13.14M 91.59M 35.24M 456M 35.2M 34.42M 1.45B
Net income -198M -25.26M -21.88M -20.69M -18.73M -35.15M -2.42B -35.42M -247M -94.99M -1.23B -94.88M -92.78M -3.92B -68.78M -8.77M -7.59M -7.18M -6.5M -12.2M -841M -12.29M -85.7M -32.97M -426M -32.93M -32.2M -1.36B
Net Debt 169M 21.53M 18.65M 17.64M 15.97M 29.97M 2.07B 30.19M 210M 80.98M 1.05B 80.89M 79.09M 3.34B 383M 48.8M 42.27M 39.97M 36.19M 67.92M 4.68B 68.43M 477M 184M 2.37B 183M 179M 7.57B
Logo China Biotech Services Holdings Limited
China Biotech Services Holdings Ltd, formerly Rui Kang Pharmaceutical Group Investments Ltd, is an investment holding company principally engaged in the provision of medical health check services. The Company operates its business through six segments. The Medical and Health Related Services segment provides medical laboratory testing services and health check services. The Insurance Brokerage segment is engaged in the provision of brokerage services. The Immunotherapy segment provides tumor immune call therapy, immune cell storage and health management services. The Pharmaceutical Products segment is engaged in the manufacture, research and development, sale and distribution of health related and pharmaceutical products. The Securities segment is engaged in the trading of securities. The Others segment is engaged in the money lending business and provision of logistic services.
Employees
166
Date Price Change Volume
26-09-15 HK$0.6000 0.00% 20,000
26-09-15 HK$0.6000 -4.76% 35,000
26-09-14 HK$0.6300 +3.28% 65,000
26-09-11 HK$0.6100 -0.81% 90,000
26-09-10 HK$0.6150 +0.82% 65,000
  1. Stock Market
  2. Stocks
  3. 8037 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!